NCT01445535 2021-11-03Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed15 enrolled 18 charts